PRESS RELEASES

2017 VIEW MORE
28 July 2017
 - TiGenix Transparency information EN - NL
29 June 2017
 - TiGenix opens US headquarters in Cambridge, MA (EN - NL - FR - ES)
23 June 2017
 - TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland (EN - NL - FR - ES)
20 June 2017
 - Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients (EN - NL - FR - ES)
15 June 2017
 - TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis (EN - NL - FR - ES)
13 June 2017
 - TiGenix Launches Global Phase III Trial for Cx601 (EN - NL - FR - ES)
12 June 2017
 - TiGenix announces final equity payment for cardiac platform acquisition (EN - NL - FR - ES)
1 June 2017
 - TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York (EN - NL - FR - ES)
31 May 2017
 - TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure (EN - NL - FR - ES)
17 May 2017
 - TiGenix to participate at international scientific and industry conferences (EN - NL -FR - ES)
12 May 2017
 - Convening notice to the extraordinary shareholders' meeting to be held on 1 June 2017 (EN - NL)
11 May 2017
 - TiGenix to present at Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas (EN - NL - FRES)
10 May 2017
 -

TiGenix to present at the Crohn’s and Colitis Foundation’s Novel Technologies in Inflammatory Bowel Disease workshop in New York (EN - NL - FRES)

4 May 2017
 - TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week (EN - NL - FR - ES)
2 May 2017
 - Convening Notice to the Annual Shareholders Meeting to be held on 1 June 2017 (EN -  NL)
7 April 2017
 - Convening notice to 9 May 2017 extraordinary shareholders' meeting (EN -  NL)
6 April 2017
 - TiGenix reports 2016 full year results (NL - FR - EN) - Financial Statements 2016 (EN)  
5 April 2017
 - Key Investor Conferences (EN - FR - NL)
29 March 2017
 - Appointment statutory auditor – Public tender (EN - NL)
13 March 2017
 - TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction (NL -  FR - EN)
9 March 2017
 - TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial  (EN - FR - NL)
7 March 2017
 - Global Phase III Trial Protocol (EN - FR - NL)
6 March 2017
 - TiGenix Provides Update on Cx601 Marketing Authorization Application procedure in Europe (EN - FR - NL)
1 March 2017
 - TiGenix to present at Cowen’s 37th Annual Health Care Conference in Boston (FR - NL - EN)
17 February 2017
 - Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601 (EN - FR - NL)
6 February 2017
 - TiGenix announces acceptance of Cx601 abstract for oral presentation at 12th Congress of ECCO (FR - NL - EN)
31 January 2017
 - TiGenix Enrolls First Patient in Phase Ib/IIa Clinical Trial of Cx611 in Severe Sepsis (FR - NL - EN)
9 January 2017
 - Transparency notification (NL - EN)
2016 VIEW MORE
29 December 2016
 - TiGenix Press Release Transparency information (EN - NL)
23 December 2016
 - TiGenix: notice in relation to the convertible bonds due 2018 (FR - NL - EN)
22 December 2016
 - TiGenix Submits Day 120 Responses to European Medicines Agency for Cx601 Marketing Authorization (EN - NL - FR - ES)
21 December 2016
 - Takeda Exercises its Option to Develop and Commercialize Cx601 in both Japan and Canada (EN - NL - FR)
20 December 2016
 - Takeda makes €10 million equity investment in TiGenix (FR - DU - EN)
20 December 2016
 - TiGenix announces closing of NASDAQ IPO (EN - NL - FR - ES)
15 December 2016
 - TiGenix raises $35.65 million gross proceeds with NASDAQ IPO (EN - DU - FR - ES)
5 December 2016
 - TiGenix announces launch of proposed initial public offering in the United States (EN - DU - FR)
26 October 2016
 - TiGenix provides update on proposed initial public offering in the United States (EN - DU - FR)
26 October 2016
 - TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (EN - NL)
17 October 2016
 - TiGenix Announces Orphan Drug Designation (ODD) for Cx601 in Switzerland (EN - NL - FR)
22 September 2016
 - TiGenix Appoints Dr. June Almenoff to its Board of Directors (EN - NL - FR)
20 September 2016
 - TiGenix Business and Financial Update for the First Half 2016 (EN - NL - FR)
2 August 2016
 - Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease (EN - NL - FR)
20 July 2016
 - Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix (EN - NL)
5 July 2016
 - Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease (EN - NL - FR - ES)
5 July 2016
 - TiGenix reconfirms its strategic focus on its allogeneic stem cell platforms (EN - NL - FR)
17 June 2016
 - TiGenix announces six-month Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction (EN - NL - FR)
16 June 2016
 - TiGenix CEO Eduardo Bravo assumes leadership of European Biopharmaceutical Enterprises (EBE) (EN - NL - FR)
18 May 2016
 - TiGenix Cx601 positive Phase III results to be presented at Digestive Disease Week in the USA (EN - NL - FR)
3 May 2016
 - Convening notice to the annual shareholders’ meeting to be held on 2 june 2016 (EN - NL)
12 April 2016
 - TiGenix reports 2015 full year results (EN - NL - FR) - Webcast - Financial statement (EN)
25 March 2016
 - Transparency Information (EN - NL)
22 March 2016
 - TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (EN - NL)
18 March 2016
 - TiGenix: notice in relation to the convertible bonds due 2018 (EN - NL - FR)
17 March 2016
 - TiGenix Presents 24 Week Results of its Cx601 Phase III Trial at ECCO 2016 (EN - NL - FR)
11 March 2016
 - Listing prospectus - Registration document (EN - NL)
11 March 2016
 - Listing prospectus - Securities transaction note (EN - NL)
11 March 2016
 - Listing prospectus - Summary note (EN - NL)
10 March 2016
 - TiGenix successfully raises €23.75 million in private placement (EN - NL - FR)
9 March 2016
 - TiGenix provides update on proposed initial public offering in the United States (EN - NL - FR)
9 March 2016
 - TiGenix to raise capital via a private placement of new shares (EN - NL - FR)
7 March 2016
 - TiGenix announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn’s disease patients (EN - NL - FR)
2 March 2016
 - TiGenix submits MAA to EMA for Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients (EN - NL - FR)
23 February 2016
 - TiGenix obtains commercial production license for Cx601 (EN - NL - FR)
11 January 2016
 - TiGenix announces acceptance of Cx601 abstract for presentation at ECCO 2016 Congress (EN - NL - FR)
8 January 2016
 - TiGenix participates in key conferences in the first half of 2016 (EN - NL - FR)
2015 VIEW MORE
28 December 2015
 - TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007 (EN - NL)
22 December 2015
 - TiGenix files Registration Statement for proposed initial public offering in the United States (EN - NL - FR)
18 December 2015
 - Transparency information (EN - NL)
8 December 2015
 - Transparency notification (EN - NL)
3 December 2015
 - Transparency Information (EN - NL)
30 November 2015
 - Transparency Information (EN - NL)
25 November 2015
 - Successful raise by TiGenix: EUR 8.7 million in private placement (EN - NL - FR - ES)
25 November 2015
 - Special board report (EN - NL)
25 November 2015
 - TiGenix to raise capital via a private placement of new shares (EN - NL - FR - ES)
19 November 2015
 - TiGenix completes enrolment of its Phase I/II study in acute myocardial infarction (EN - NL - FR)
2 November 2015
 - SEPCELL project in severe sepsis receives €5.4M grant from the EU’s Horizon 2020 (EN - NL - FR)
23 September 2015
 - AlloCSC-01 Phase I Data Presented at the Congress of the European Society of Cardiology (EN - NL - FR)
15 September 2015
 - H1 2015 Business and Financial Update (EN - NL - FR) - Financial statements (EN - NL - FR) - Webcast - Presentation - Interim Financial Statements (EN) - Interim Financial Statements (NL)
10 September 2015
 - TiGenix to host webcast for its 2015 half-year results on 15 September (EN - NL - FR)
9 September 2015
 - Tigenix to participate or present at key conferences in H2 2015 (EN - NL - FR)
23 August 2015
 - TiGenix announces Cx601 meets primary endpoint in pivotal Phase III trial (EN - NL - FR)
7 August 2015
 - TiGenix obtains FDA’s endorsement through Special Protocol Assessment for its Cx601 Phase III registration trial in the US (EN - NL - FR)
7 August 2015
 - TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007 (EN - NL)
31 July 2015
 - Transparency Information (EN - NL)
31 July 2015
 - Dirk Büscher and José Terencio resign from TiGenix board of directors (EN - NL - FR)
30 July 2015
 - TiGenix expands pipeline and enters the cardiology field with clinical-stage company acquisition (EN - NL - FR)
3 July 2015
 - Notice in relation to the convertible bonds due 2018 (EN - NL - FR)
11 June 2015
 - TiGenix starts Cx601 Marketing Authorisation Application process (EN - NL - FR)
28 May 2015
 - Safety and tolerability of Cx611 confirmed in Phase I sepsis challenge trial (EN - NL - FR)
13 May 2015
 - Convening notice to the extraordinary shareholders' meeting to be held on 2 June 2015 (EN - NL)
13 May 2015
 - TiGenix: notice in relation to the convertible bonds due 2018 (EN - NL - FR)
27 April 2015
 - TiGenix reports 2016 full year results (EN - NL - FR) - Financial statement (EN)
12 April 2015
 - Key Investor Conferences (EN - NL - FR)
8 April 2015
 - USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas (EN - NL - FR)
20 March 2015
 - Convening notice to the annual and the extraordinary shareholders' meetings to be held on 20 April 2015 (EN - NL)
17 March 2015
 - TiGenix reports its full year 2014 results (EN - NL - FR) - Presentation - Webcast - Financial statement (EN)
12 March 2015
 - TiGenix completes treatment in Phase I sepsis challenge trial with Cx611 (EN - NL - FR)
27 February 2015
 - TiGenix NV successfully places EUR 25 million convertible bonds (EN - NL - FR - ES)
26 February 2015
 - TiGenix launches an offering of EUR 25 million convertible bonds (EN - NL - FR - ES)
26 February 2015
 - Special report of the Board of Directors (EN - NL)
23 February 2015
 - TiGenix’s Phase III trial design for Cx601 endorsed by President-Elect of ECCO (EN - NL - FR)
12 February 2015
 - TiGenix and Lonza sign agreement for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn’s disease (EN - NL - FR)
2 February 2015
 - TiGenix participates in key conferences in the first half of 2015 (EN - NL - FR)
22 January 2015
 - European Patent Office issues key patent to TiGenix for expanded adipose-derived stem cell compositions (EN - NL - FR)
2014 VIEW MORE
22 December 2014
 - TiGenix submits its pivotal US trial design for Cx601 to the FDA for Special Protocol Assessment (EN - NL - FR)
10 December 2014
 - TiGenix starts Phase I trial of Cx611 in severe sepsis (EN - NL - FR)
12 November 2014
 - TiGenix completes patient recruitment for the European Phase III trial of Cx601 ahead of schedule (EN - NL - FR)
4 November 2014
 - Q3 2014 Business and Financial Update (EN - NL - FR)
17 October 2014
 - TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007 (EN - NL)
15 September 2014
 - Tigenix to participate or present at key conferences in H2 2014 (EN - NL - FR)
8 September 2014
 - European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601 (EN - NL - FR)
1 September 2014
 - TiGenix appoints Chief Medical Officer and Vice President Medical Affairs and New Product Commercialisation (EN - NL - FR)
27 August 2014
 - Correction to H1 2014 Business and Financial Update (EN - NL - FR)
26 August 2014
21 August 2014
 - Convening Notice to the Extraordinary Shareholders' Meeting of 8 September 2014 (EN - NL)
10 July 2014
 - Convening Notice to the Extraordinary Shareholders' Meeting of 12 August 2014 (EN - NL)
1 July 2014
 - European Medicines Agency renews Marketing Authorisation for ChondroCelect (EN - NL - FR)
30 June 2014
 - TiGenix announces the clinical development of Cx611 (EN - NL - FR) - Presentation - MP3
2 June 2014
 - TiGenix completes the sale of its Dutch manufacturing facility to PharmaCell (EN - NL - FR)
13 May 2014
 - TiGenix Business and Financial Update for the first quarter of 2014 (EN - NL - FR)
3 May 2014
 - TiGenix reports 2016 full year results (EN - NL - FR) - Financial statement (EN)
27 April 2014
 - Convening notice to 9 May 2017 extraordinary shareholders' meeting, Convening notice to 9 May 2017 extraordinary shareholders' meeting (EN - NL - FR)
17 April 2014
 - VFB e-Flash: interview with Eduardo Bravo (EN)
4 April 2014
 - Convening Notice to the Extraordinary Shareholders' Meeting of 22 April 2014 (EN - NL)
3 April 2014
 - TiGenix licenses exclusive marketing and distribution rights for ChondroCelect to Sobi (EN - NL - FR)
21 March 2014
 - Convening Notice to the Annual Shareholders' Meeting - 22 April 2014 (EN - NL)
11 March 2014
 - TiGenix Full Year 2013 Results (EN - NL - FR) - MP3 - Financial Statement EN - FY 2013 Results Presentation (EN)
28 February 2014
 - Notice Extraordinary Shareholder Meeting on April 2, 2014 (EN - NL)
4 February 2014
 - TiGenix reaches major cell therapy milestone with 1000th implant of ChondroCelect (EN - NL - FR)
24 January 2014
 - TiGenix to sell Dutch manufacturing facility to PharmaCell (EN - NL - FR)
21 January 2014
 - TiGenix to present at BIO CEO & Investor Conference & key meetings in H1 2014 (EN - NL - FR)
2013 VIEW MORE
29 December 2013
 - Transparency notice, Nov. 29, 2013 (EN - NL)
23 December 2013
 - TiGenix secures EUR 10 million in financing from Kreos Capital (EN - NL - FR)
5 December 2013
 - TiGenix appoints Gri-Cel CEO Dirk Büscher and COO José Terencio to board of directors (EN - NL - FR)
26 November 2013
 - Transparency notice, Nov. 26, 2013 (EN - NL)
22 November 2013
 - TiGenix completes EUR 12 million capital increase with strategic investor Grifols (EN - NL - FR)
20 November 2013
 - TiGenix Raises EUR 12 million via a Private Placement of New Ordinary Shares (EN - NL - FR)
5 November 2013
 - TiGenix Q3 2013 Results (EN - NL - FR)
11 October 2013
 - Transparency information October 11, 2013 (EN - NL)
10 September 2013
 - TiGenix to present at ACR plenary and other key conferences (EN - NL - FR)
20 August 2013
14 August 2013
 - Transparency Information (EN - NL)
2 August 2013
 - Transparency information August 2, 2013 (EN - NL)
18 July 2013
 - TiGenix Raises EUR 6.5 million in Private Placement (EN - NL - FR - ES)
17 July 2013
 - TiGenix to Raise Capital via a Private Placement of New Ordinary Shares (EN - NL - FR - ES)
7 June 2013
 - TiGenix provides ChondroCelect update (EN - NL - FR)
31 May 2013
 - Transparency Information (EN - NL)
17 May 2013
 - Transparency Information (EN - NL)
14 May 2013
 - TiGenix Reports Business & Financial Results for the First Quarter 2013 (EN - NL - FR)
22 April 2013
 - TiGenix reports positive Phase IIa study results in refractory rheumatoid arthritis with allogeneic stem cell product Cx611 (EN - NL - FR)
12 March 2013
 - TiGenix Full Year 2012 Results (EN - NL - FR) - Financial statements (EN - NL - FR) - Presentation
12 March 2013
 - TiGenix to obtain reimbursement in Spain for ChondroCelect (EN - NL - FR)
12 February 2013
 - TiGenix to present at 15th Annual BIO CEO & Investor Conference (EN - NL - FR)
4 February 2013
 - 4 February 2013 - TiGenix to Present at Key Conferences H1 2013 (EN - NL - FR - ES)
29 January 2013
 - TiGenix successfully renews GMP license for stem cell manufacturing facility in Madrid (EN - NL - FR - ES)
22 January 2013
 - Notice Extraordinary Shareholder Meeting on February 26, 2013 (EN - NL)
9 January 2013
 - Transparency information (EN - NL)
2012 VIEW MORE
20 December 2012
 - TiGenix Completes Private Placement Raising EUR 6.7 million (EN - NL - FR)
19 December 2012
 - TiGenix to Raise Capital via a Private Placement of New Ordinary Shares (EN - NL - FR - ES)
19 December 2012
 - TiGenix reports positive interim safety results of Cx611 Phase IIa rheumatoid arthritis study (EN - NL - FR - ES)
14 December 2012
 - TiGenix Reacts to Rumors (EN - NL - FR - ES)
23 November 2012
 - TiGenix closes biomaterial unit to fully focus on advanced cell therapy programs (EN - NL - FR - ES)
13 November 2012
 - TiGenix signs agreement for commercialization of ChondroCelect in the Middle East (EN - NL - FR - ES)
8 November 2012
 - TiGenix Reports Business & Financial Results for the Third Quarter 2012 (EN - NL - FR - ES)
9 October 2012
 - TiGenix announces publication of Cx601 Phase I/II study in International Journal of Colorectal Disease (EN - NL - FR - ES)
25 September 2012
 - TiGenix’s new European production facility obtains EMA approval for commercial production of ChondroCelect (EN - NL - FR - ES)
20 September 2012
 - TiGenix appoints Jean Stéphenne chairman & Russell Greig member of board of directors (EN - NL - FR - ES)
24 August 2012
 - Transparency Information (EN - NL)
23 August 2012
 - TiGenix Half Year 2012 Results (EN - NL - FR - ES) - Financial statements (EN - NL - FR - ES) - Presentation
8 August 2012
 - TiGenix completes patient enrollment in Phase IIa rheumatoid arthritis study (EN - NL - FR - ES)
27 July 2012
 - Transparency information (EN - NL)
17 July 2012
 - TiGenix signs up 4th major hospital in the Netherlands for ChondroCelect and obtains national reimbursement retroactive per January 1, 2011 (EN - NL - FR - ES)
10 July 2012
 - TiGenix enrolls first patients in pivotal Phase III trial with lead product Cx601 in perianal fistulas (EN - NL - FR - ES)
6 July 2012
 - Transparency Information (EN - NL)
2 July 2012
 - TiGenix reports positive results of Cx621 Phase I (EN - NL - FR - ES)
8 June 2012
 - TiGenix obtains national reimbursement in the Netherlands for breakthrough cartilage therapy ChondroCelect® (EN - NL - FR - ES)
31 May 2012
 - Transparency Information (EN - NL)
15 May 2012
 - TiGenix Reports Business & Financial Results for the First Quarter 2012 (EN - NL - FR - ES)
8 May 2012
 - TiGenix to Present at Key Conferences - Spring 2012 (EN - NL - FR - ES)
24 April 2012
 - TiGenix obtains manufacturing license for European production facility (EN - NL - FR - ES)
17 April 2012
 - TiGenix rheumatoid arthritis Phase IIa study successfully passes last safety hurdle (EN - NL - FR - ES)
17 April 2012
 - TiGenix completes third and final phase of the Orthomimetics acquisition (EN - NL - FR - ES)
17 April 2012
 - Transparency Information (EN - NL)
10 April 2012
 - TiGenix appoints VP commercial (EN - NL - ES)
15 March 2012
 - TiGenix Full Year 2011 Results (EN - NL - FR - ES) - Financial statements (EN - NL - FR - ES) - Presentation
16 February 2012
 - TiGenix announces changes in management responsibilities (EN - NL - FR - ES)
1 February 2012
 - TiGenix rheumatoid arthritis Phase IIa study opens third and last cohort (EN - NL - FR - ES)
9 January 2012
 - TiGenix reports positive results of ChondroCelect compassionate use program (EN - NL - FR - ES)
2011 VIEW MORE
23 December 2011
 - TiGenix obtains EUR 2.9 million FP7 grant to fund development of Cx611 in rheumatoid arthritis (EN - NL - FR - ES)